Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis

Study Identifier
P12-769
CT.gov Identifier
NCT01412021
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Protocol
Available Language(s): English
Download document(s)
Statistical Analysis Plan
Available Language(s): English
Download document(s)
Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Juvenile Idiopathic Arthritis
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    N/A - 99 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * All patients with Juvenile idiopathic arthritis who are not responding well to conventional therapy and receive Humira will be enrolled in the survey
    Exclusion Criteria:
    * Contraindications according to the Package Insert * Patients who have serious infections * Patients who have tuberculosis * Patients with a history of hypersensitivity to any ingredient of Humira * Patients who have demyelinating disease or with a history of demyelinating disease * Patients who have congestive cardiac failure

    Protocol Summary

    This study of Humira will be conducted to clarify the following with regard to the treatment of juvenile idiopathic arthritis affecting multiple joints with this drug:

    • Unknown adverse drug reactions (especially important adverse drug reactions)
    • Incidence and conditions of occurrence of adverse reactions in the clinical setting
    • Factors that may affect the safety and effectiveness of Humira

    Study Locations

    No locations found.